- 著者
- Tomoko YAESHIMA Sachiko TAKAHASHI Nobuko MATSUMOTO Norioi ISHIBASHI Hirotoshi HAYASAWA Hisakazu IINO
- 出版者
- JAPAN BIFIDUS FOUNDATION
- 雑誌
- Bioscience and Microflora (ISSN:13421441)
- 巻号頁・発行日
- vol.16, no.2, pp.73-77, 1997 (Released:2010-06-28)
- 参考文献数
- 26
- 被引用文献数
- 32 42
Yogurt containing Bifidobacterium longum BB536 (designated as Bifidus yogurt) was administered to adult volunteers and its effects on the intestinal environment with reference to fecal microflora, ammonia levels, fecal characteristics (color, consistency) and defecation frequency were examined. Bifidus yogurt was manufactured by fermenting milk with B. longum BB536, Streptococcus thermophilus STH-450 and Lactobacillus delbrueckii subsp. bulgaricus LBU-108. Standard yogurt manufactured using only S. thermophilus STH-450 and L. delbrueckii subsp. bulgaricus LBU-108 was used as the control diet. Eleven women volunteers were assigned as subjects to test the effects of Bifidus yogurt on the intestinal environment. Thirty-nine women volunteers were assigned as subjects to test the effects on fecal characteristics and defecation frequency. The volunteers were each administered 100 g of standard yogurt per day for two weeks. After a two-week interval period, each subject was administered 100 g of Bifidus yogurt per day for the subsequent test period. The period of administration of Bifidus yogurt was 2 weeks for testing effects on the intestinal environment and 3 weeks for testing effects on fecal characteristics and defecation frequency. The administration of Bifidus yogurt was effective to increase the number and relative percentage of fecal bifidobacteria significantly. The fecal ammonia concentration tended to decrease and fecal organic acid content tended to increase. The defecation frequency was significantly increased by Bifidus yogurt. The color of the feces changed to yellow and the consistency changed to soft. The administration of Bifidus yogurt was effective to improve the intestinal environment, fecal characteristics and defecation frequency.
- 著者
- Yvan Vandenplas Genevieve Veereman-Wauters Elisabeth De Greef Tania Mahler Thierry Devreker Bruno Hauser
- 出版者
- JAPAN BIFIDUS FOUNDATION
- 雑誌
- Bioscience and Microflora (ISSN:13421441)
- 巻号頁・発行日
- vol.30, no.4, pp.111-117, 2011 (Released:2011-11-17)
- 参考文献数
- 50
- 被引用文献数
- 2 2
Western medicine has only recently discovered that the intestinal microbiota is a major determinant of the well-being of the host. Although it would be oversimplifying to limit the benefits of breastfeeding compared to cow milk based infant formula to differences in gastrointestinal flora, the impact of the latter has been demonstrated beyond doubt. As a consequence, gastro intestinal flora manipulation with pre- and probiotics added to infant formula or food (mainly milk based products) and/or with food supplements have become a priority area of high quality research. The composition of intestinal microbiota can be manipulated with "biotics": antibiotics, prebiotics and probiotics. Commercialised pre- and probiotic products differ in composition and dose. Major threats to the concept of developing a major role for intestinal microbiota manipulation on health are the commercialisation of products claiming health benefits that have not been validated. Legislation of food supplements and medication differs substantially and allows commercialisation of poor quality food supplements, what will result in negative experiences. Medicinal products can only be advertised for which there is scientific proof of benefit that has been demonstrated with "the same product with the same dose in the same indication". Specificity of prebiotics and probiotics strains and product specificity are of importance, although high quality evidence for this assertion is missing. Dose-efficacy studies are urgently needed. Probiotics are "generally regarded as safe", but side effects such as septicemia and fungemia have sometimes been reported in high-risk situations.